Meeting
2024 ASCO Annual Meeting
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.
Authors
Joachim Aerts
Department of Pulmonary Diseases, Erasmus MC, Rotterdam, Netherlands
Joachim Aerts , Luis G. Paz-Ares , Carole Helissey , Federico Cappuzzo , Gilles Quere , Dariusz Kowalski , Jose Carlos Benitez Sr., Florian Guisier , Benjamin Besse , Shirish M. Gadgeel , Thomas Wehler , Ignacio Gil-Bazo , Michael Jon Chisamore , Cem Gorgun , Ilhan Celik , Marie Holst Mørch , Patricia Garrido Castro , Teng Jin Ong , Enriqueta Felip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT05117242
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2533)
DOI
10.1200/JCO.2024.42.16_suppl.2533
Abstract #
2533
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2016 ASCO Annual Meeting
Pembrolizumab in advanced endometrial cancer: preliminary results from the phase 1b KEYNOTE-028 study.
First Author: Patrick Alexander Ott
Poster
2024 ASCO Breakthrough
Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study.
First Author: Ying Cheng
First Author: Igor Tsaur